Introduction
Epidermis, the outermost layer of skin, deploys an epidermal permeability barrier to prevent excess water loss 1 and ingress of pathogens, allergens and xenotoxic agents. 2 The presence of this barrier is necessary for survival of mammalian species in a terrestrial environment. More precisely, lipid lamellar membrane structures in the extracellular domain of the stratum corneum (SC) are responsible for barrier function. Heterogeneous molecular species of ceramide (Cer) are key constituents that form lamellar structures. The most unique and essential Cer species contain very long omega (ω)-hydroxy fatty acids (ω-OH VLCFA) (hydrocarbon chain length ranging from [28] [29] [30] [31] [32] [33] [34] . Such very long chain lengths of fatty acids (VLCFA) have been found in selected tissues, such as retina, 3 brain, 4 testis, 5 spermatozoa 6 and epidermis (reviewed in ref. 7) , while ω-OH VLCFA as well as Cer and their glucosylated counterparts containing ω-OH VLCFA have been found only in differentiated layers of the epidermis of terrestrial Heterogeneous molecular species of epidermal ceramide (Cer) play critical roles in forming a competent permeability barrier of lamellar membrane structures in the stratum corneum, which is a prerequisite to preventing excess water loss for terrestrial mammals. Lipids containing very long chain lengths of fatty acids (vLCFA) (hydrocarbon chain lengths over 28) have been found in selected tissues, including epidermis. in particular, ω-hydroxy (ω-OH) vLCFA as well as Cer containing ω-OH vLCFA and ω-O-acylCer (acylCer) are unique to epidermis. The fatty acid elongation system that generates vLCFA, which requires four enzymatic steps, has been characterized, while recent studies using transgenic animals have further revealed the importance of ω-OH Cer species for barrier formation and have also elucidated the synthetic pathway of these essential Cer species in conjunction with vLCFA metabolism. This review article discusses the generation of vLCFA and unique epidermal Cer species containing vLFCA in the relation to their roles in epidermis. 
VLCFA Biosynthesis
Lipids are divided into neutral lipids and complex lipids. Fatty acids (FA) are constituents of both of these lipid species. Neutral lipids are generated from alcohol and FA, i.e., acylglyceride (glycerol + FA), wax (primary alcohol + long chain FA), Cer (long chain amino alcohol + FA) and sterol esters (sterol + FA). Complex lipids include phospholipids and glycolipids, which contain either a glycerol or sphingoid base (long chain amino alcohol) backbone structure, respectively. FA serve as a major source of energy as well as structural components of membranes as both free forms and esterified forms, and also act as nuclear hormone ligands to regulate cellular functions.
FA with carbon chain lengths up to C16 are synthesized by the FA synthase complex localized in cytosolic fraction (FAS-I) and mitochondria (FAS-II) 8 (c.f. see in the review of this series by Dr. Denis Khnykin). Synthesized FA or FA supplied from dietary sources are then elongated by membrane-associated FA chainelongation system at the endoplasmic reticulum (ER). 8 Similar to the FA synthase complex, the FA chain-elongation system uses four metabolically-linked enzymes for chain elongation: 3-ketoacyl-CoA synthase (Condensation), 3-keto-acyl-CoA reductase (Reduction), 3-hydroxyacyl-CoA hydrase (Dehydration) and 2,3 enoyl-CoA reductase (Reduction). Chain extension occurs via two carbons per cycle. While the fatty acid synthase (FAS-I) is a single, homodimeric, multifunctional protein, both the FA elongation complex and FAS-II consist of four different classes of enzymes.
The enzymes that catalyze these four steps have been recently characterized in mammals.
(1) Condensation (1 st Step). ELOs that are responsible for the condensation step first were found in yeasts, and later in plants and mammals. Seven ELO homologues (ELOVL 1-7) have been identified in mammals. ELOVLs exhibit tissue-specific specific distribution. 15 While the expression profile of ELOVL7 has not been elucidated, distribution of the other six ELOVL have been examined, i.e., ELOVL1, ELOVL5 and ELOVL6 are ubiquitously expressed, while ELOVL2, ELOVL3 and ELOVL4 highly express in liver/testis, skin/liver and retina/brain/skin, respectively (note: whole skin was used in this study). 24 Yet, the expression profile/level of other ELOVLs has not been completely defined in comparison to other tissues.
ELOVLs contain five transmembrane regions, a histidine-rich motif (HXXHH) and a ER retention signal (KKXX) (reviewed in ref. 7) .
The distinctive roles of each ELOVL in generating different VLCFA species have been elucidated, while recent studies using different chain lengths of FA as substrates further clarified the substrate specificities and their products.
15 ELOVL1, ELOVL3, ELOVL4 and ELOVL6 account for the elongation of both saturated and monosaturated VLCFA synthesis, i.e., ELOVL1, substrate specificity: C20-26, C20-22:1; ELOVL3, C18-26, C20-22:1; and ELOVL6, C12-16, C18:1, while ELOVL2 and ELOVL5 elongate polyunsaturated FA (PUFA), i.e., C20-22:4, C20-22:5 and ELOVL5, C18-20:4, C20:5.
15 ELOVL4 utilizes both saturated and PUFA as substrates (≥C24, C24:4, C24:5, C24:6) to synthesize VLCFA.
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Roles of VLCFA in Epidermis
In addition to free VLCFA form, VLCFA are utilized as constituents of amide-like FA in Cer and GlcCer in epidermis. In particular, acylceramides (acylCer) ( Fig. 1) and their glucosylated form [acylglucosylceramide (acylGlcCer)] that contain ω-OH VLCFA are unique to epidermis. Moreover, ω-OH residue is esterified by the predominantly essential FA, linoleate, deficiency of which results in abnormal permeability function. 16 Therefore, roles of acylCer and acylGlcCer in skin have been paid attention to since the discovery of these molecules in the early 1980s, [17] [18] [19] and the importance of acylCer as an epidermal permeability barrier constituent has mounted. In vitro studies using reconstituted membrane models demonstrated the role of acylCer in the establishment of the long periodicity phase (13 nm) that represents normal lamellar membrane structures in the extracellular domains of barrier competent SC. 20 Indeed, decreases in acylCer have been shown in cutaneous diseases with abnormal permeability barrier function, e.g., atopic dermatitis, [21] [22] [23] senile xerosis, 24 lamellar ichthyosis, 25 Sjögren-Larsson syndrome 25 and Dorfman-Chanarin syndrome. 26 Moreover, recent findings in cutaneous diseases and their animal models have further suggested the importance of acylCer for terrestrial mammalian survival. A mutant Elovl4-knock-in mouse, a model of a rare form of autosomal dominant Stargardt macular dystrophy (STGD3), which lacks normal VLCFA generation due to a single 5 bp deletion coded ER retention signal, 27 results in the failure to form FA elongation complex. The homozygous mutant Elovl4 knock-in mouse lacks both acylCer and normal lamellar membranes, and displays abnormal lamellar body contents and postnatal lethality within 4 hrs due to excess water loss. 28, 29 Elovl4-null mice also show similar features. 30 Whereas VLCFA are contained in distribution and distinct substrate specificities. Further details of ELOVLs are described in the next section (see below).
(2) Reduction (2 nd Step). 3-ketoacyl-CoA reductase (KAR), which has a homologous relationship with the short chain dehydrogenase superfamily, catalyzes 3-ketoacyl-CoA to 3-hydroxyacyl-CoA. The gene encoding this enzyme is a homologue of yeast Ybr159p.
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(3) Dehydration (3 rd Step). Four 3-hydroxyacyl-CoA dehydratases (HACD) that catalyze the dehydration of the 3-hydroxyacyl-CoA have been characterized in mammals. Both HACD1 and HACD2 have similarities in their sequences to yeast Phs. Like ELOVLs, four HASDs show tissue specific expression profiles. 10 Although substrate specificities of HACD have not been completely elucidated, HACD2 and HACD3 are ubiquitously expressed, and the other two HACD levels, HACD1 and HACD4, are high in heart and leukocyte in humans, 10 suggesting that appropriate HACDs are likely utilized for specific FA elongation in combination with ELOVL expressed in the same tissue. Yet, expression profile on HACD in epidermis has not been characterized.
(4) Reduction (4 th Step). The trans-2,3-enoyl-CoA reductase (TER) that catalyzes 3-hydroxyacyl-CoA to fatty acyl-CoA, is 32% identical to the yeast trans-2,3-enoyl-CoA reductase and a homologue of Yeast Tsc13p. 9 Although all other FA elongation enzymes (step 1 through 3) contain a ER retention motif (KKXX), TER does not have such motif. 9 In contrast to ELOVLs and HACDs, only two reductases (KAR and TER) that account for the second and last step of elongation have been identified. It is unclear whether these identified reductases serve to reduce any chain lengths of 3-ketoacyl-CoA or 3-hydroxyacyl-CoA.
VLCFA in Tissues
VLCFA (C26-40) are present as saturated, monounsaturated and polyunsaturated forms. In contrast to FA containing hydrocarbon chain lengths of 16-22, which are widely distributed in most living organisms including mammals, VLCFA (C26-40) are found in limited species and tissues mainly in yeasts, plants (seed oils, plant waxes, cutin, suberin) and mammals (brain, retina, skin, hair, testis and spermatozoa). Brain and retina contain VLCFA-PUFA in phosphatidylcholine, 4, 11 while VLCFA are contained in Cer, glycosphingolipids and sphingomyelins (SM) in spermatozoa. 12, 13 VCLFA have been shown predominantly in Cer and glucosylceramide (GlcCer), but trace levels are in SM, in epidermis. 14 
ELOVL
ELOVL have been the most characterized enzymes in the FA elongation complex, including substrate specificities and expression profile in tissues. Pertinently, physiological and pathological roles of certain ELOVL in mammals, including in skin, have been elucidated. Hence, ELOVLs are further discussed in this review below.
Seven mammalian homologues (ELOVL1-7) of the yeast ELO gene products exhibit substrate specificities as well as tissue
VLCFA synthesis. Elovl3-, Elovl4-, Elovl5-,
37 Elovl6-null mice, 38 and mutant Elov4 knock-in mice have been generated to date (November 2010). Only homozygous Elovl4-null and Elov4 knock-in mice are lethal due to epidermal permeability barrier defects. [28] [29] [30] VLCFA containing hydrocarbon chain length of 28 levels do not differ in epidermis of normal Wt mice and of homozygous mutant ELOVL4 knock-in mice that lack acylCer production. 28 However, since increased VLCFA containing hydrocarbon chain length of 26 and absence of >C28 are evident in epidermis from homozygous mutant Elovl4-knock-in mice, 28 ELOVL4 is responsible for VLCFA being required for acylCer amide-linked FA production. 28 Skin phenotypes and epidermal Cer profiles of Elovl5-null (-/-), 37 and Elovl6-null 38 mice are not reported, while those mice are not neonatal lethal. Although Elovl3-null mice show normal epidermal permeability barrier function at basal condition and contain normal levels of acylCer, a barrier recovery was delayed following acute barrier perturbation, 39 suggesting that ELOVL3 function is not compensated by other ELOVLs. Therefore, both ELOVL1, 3, 6 and/or 7 can be involved in generate substrate of VLCFA catalyzed by ELOVL4, and ELOVL1, 3, 6 and/or 7, expressed in skin, can compensate each other to synthesize VLCFA, if any of them are defective.
Cer synthesis. Cer are synthesized primarily at the endoplasmic reticulum (ER). Sphingoid base is generated by both De novo pathway and Salvage (or recycle) pathway. De novo pathway L-serine and palmitoyl-CoA are condensed by serine palmitoyltransferase to form 3-ketosphinganine, followed by its reduction to sphinganine by 3-ketosphinganine reductase, and subsequent N-acylation of sphinganine by Cer synthase(s). 40 Six isoforms of Cer synthase (CerS 1-6) preferentially utilize selected carbon chain lengths of acyl-CoA as substrate. 41 26 CGI-58 deficient mice, a model of DorfmanChanarin syndrome, also display both acylCer and bound ω-OH Cer deficiencies in parallel with a neonatal lethal skin barrier defect 31 (c.f. see in the review of this series by Dr. Rudolf Zechner). Although triacylglyceride accumulation in the SC 32 could also contribute to altered lamellar membrane structures, VLCFA generation is not affected by lacking CGI-58 function, suggesting that acylCer rather than other Cer containing VLCFA and/or free VFCFA are more critical lipid species. The insights of Dorfman-Chanarin syndrome also led to elucidation of the synthetic pathway of acylCer (see next section). Finally, the ω-position of the amide-linked FA moiety of ω-OH Cer becomes covalently bound to the carboxy termini of cornified envelope proteins (primarily involucrin) on the external surface of the corneocyte, forming the corneocyte lipid envelope (i.e., bound form of ω-OH Cer.) (reviewed in ref. 33 ) Although the function of the corneocyte lipid envelope has not been completely defined, it has been proposed that it serves as a scaffold for the deposition of extracellular lamellar bilayers. 34 Hence, taken together with these findings, acylCer is a more physiologically important lipid species containing VLCFA compared with other Cer species and/or free VLCFA in epidermis.
AcylCer Formation
AcylCer synthesis occurs in the late stages of keratinocyte differentiation. 35, 36 In human epidermis, three distinct acylCer species which contain a different sphingoid base; i.e., sphingosine, 6-hydroxy sphingosine and 4-hydroxysphinganine (or phytosphingosine), for the acylCer species Cer 1 (EOS), Cer 4 (EOH), and Cer 9 (EOP), respectively 33 ( Fig. 1) , have been identified. AcylCer formation requires unique synthetic steps, including VLCFA synthesis, ω-hydroxylation, and ω-O-esterification (Fig. 2) . ω-O-FA esterification. While it is suggested that FA derived from triacylglyceride is utilized in the ω-O-esterification step to form acylCer, 47 both triacylglyceride, linoleate and acylCer content decline in acyl-CoA:diacylglycerol acyltransferase-2 (DGAT2)-deficient mice in parallel with abnormal permeability barrier. 48 Moreover, as described above, recent studies further suggest that linoleate produced by the lypolysis of triacylglyceride, which is facilitated by CGI-58, provides FA that is utilized for ω-O-esterification leading to acylCer formation.
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Regulation of ELOVL Expression
Increased in both acylCer/acylGlcCer generation 36 and ELOVL4 mRNA expression occur late in keratinocyte differentiation (Y. Uchida et al. unpublished data). Gene silencing of vitamin D receptor and its coactivator SRC (steroid receptor coactivator) 2 and SRC3 decreased both ELOVL3 and ELOVL4 mRNA expression in cultured primary KC. 49 Since vitamin D receptor stimulation increased KC differentiation, it remains to be resolved whether the vitamin D receptor directly binds to promoter regions of ELOVL3 and/ or ELOVL4. The regulatory mechanisms of other ELOVLs in epidermis have not been elucidated.
Similar to epidermis, a few studies about the regulation of ELOVL expression have been demonstrated in selected extracutaneous tissues as below. ELOVL1, ELOVL3 and ELOVL6 expression increase after cold stress followed by heat generation to maintain body temperature in murine brown adipose tissues. 50 Nutritional status also affects FA metabolism, including changes in ELOVL expression. 51 These alterations of ELOVL expression are due to transcriptional levels. ELOVL1 and ELOVL6 mRNA expressions are upregulated by the nuclear liver X receptor (LXR)-sterol regulatory element-binding protein (SREBP-1)-mediated mechanism cultured brown adipocytes. 50 In contrast, ELOVL3 mRNA expression is downregulated by LXR-SREBP-1 mechanism and upregulated by adrenergic stimulation. 50 Recent studies also characterized the adrenergic mechanism for ELOVL3 as synergistically enhanced by the peroxisome proliferator-activated receptor (PPAR)α activation.
52 ELOVL5 mRNA expression is increased by LXRα-SREBP-1c pathway and downregulated by PUFA. 53 expressed in skin and testis and has broad substrate specificity, including VLCFA, appears to be involved in acylCer formation. 42 Following N-acylation, the sphinganine moiety is either desaturated to a sphingenine (or sphingosine) backbone by desaturase-1 (DES-1) or hydroxylated to 4-OH sphinganine (phytosphingosine), 43 by desaturase-2 (or DES-2) or to 6-OH sphingosine by an enzyme which has not yet been identified. 44 In addition to de novo sphingoid base synthesis (through serine palimitoyltransferase), salvage pathway (or sphingosine recycling) also occurs as GlcCer and SM are hydrolyzed to Cer, followed by hydrolysis to sphingoid base and FA by ceramidases. 45 Generated sphingoid base can then be reutilized as substrates for Cer formation.
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FA ω-hydroxylation. Prior studies indicate that blockade of FA ω-hydroxylation using a specific inhibitor of P-450-type 4 isoforms, aminobenzoltriazol, causes a decrease in ω-OH Cer production and CLE formation accompanied by a barrier abnormality, 46 suggesting that P-450-type 4 isoform appears to account for FA ω-hydroxylation. Veterans Affairs Medical Center and University of California, San Francisco, CA USA) are gratefully acknowledged for critical discussions about the metabolism and roles of acylceramide in skin. These studies were supported by a National Institutes of Health Grant AR 051077.
